



The Drug Utilization Review (DUR) Board Reviewed
the Following New Drug Classes on
May 1, 2018

Therapeutic Class	Drug Name	DURB Recommendations
Hemophilia Treatment		
	<i>Hemlibra (Subcutaneous) Injection</i>	P/PA
	<i>Novoeight (Intravenous) Injection</i>	P
	<i>Nuwiq (Intravenous) Injection</i>	P
	<i>Rebinyn (Intravenous) Injection</i>	NP/PA
	<i>NovoSeven RT (Intravenous) Injection</i>	NP/PA
	<i>FEIBA (Intravenous) Injection</i>	NP/PA
Gastrointestinal Motility, Chronic		
	<i>Amitiza (Oral) Capsule</i>	P/PA
	<i>Symproic (Oral) Tablet</i>	NP/PA
Analgesics, Narcotics Long		
	<i>Kadian (Oral) Capsule</i>	NP/PA
	<i>Methadone (Oral) Tablet/Solution</i>	NP
Angiotensin Modulator Combinations		
	<i>Trandolapril/Verapamil (Oral) Tablet</i>	NP/PA
	<i>Azor (Oral) Tablet</i>	NP/PA
	<i>Tribenzor (Oral) Tablet</i>	NP/PA
Antianginal & Anti-Ischemic		
	<i>Ranexa (Oral) Tablet</i>	P/PA
Antibiotics, Vaginal		
	<i>Clindesse (Vaginal) Cream</i>	P



Therapeutic Class	Drug Name	DURB Recommendations
Anticoagulants		
	<i>Enoxaparin (Subcutaneous) Vial</i>	NP/PA
	<i>Enoxaparin (Subcutaneous) Syringe [only Non-Authorized Generic]</i>	NP/PA
	<i>Fragmin (Subcutaneous) Injection</i>	NP/PA
Antiemetic/Antivertigo Agents		
	<i>Emend (Oral) Capsule</i>	P
	<i>Trimethobenzamide (Oral) Capsule</i>	NP
	<i>Compro (Rectal) Suppository</i>	NP
	<i>Promethazine 50 mg (Rectal) Suppository</i>	NP
Antimigraine Agents, Triptans		
	<i>Naratriptan (Oral) Tablet</i>	NP
	<i>Sumatriptan (Subcutaneous) Vial, Syringes, Kit</i>	NP
Bladder Relaxant Preparations		
	<i>Flavoxate (Oral) Tablet</i>	NP
Botulinum Toxins		
	<i>Myobloc (Intramuscular) Injection</i>	NP
	<i>Xeomin (Intramuscular) Injection</i>	NP
Cephalosporins and Related Antibiotics		
	<i>Cefadroxil (Oral) Tablet</i>	NP/PA
	<i>Amoxicillin/Clavulanate (Oral) Chewable Tablet</i>	NP/PA
	<i>Augmentin 125 mg/5 mL (Oral) Suspension</i>	NP/PA
	<i>Cefaclor (Oral) Extended-Release Tablet</i>	NP/PA
	<i>Cefpodoxime (Oral) Tablet</i>	NP/PA
	<i>Cefpodoxime (Oral) Suspension</i>	NP/PA
Cytokine and CAM Antagonists		



Therapeutic Class	Drug Name	DURB Recommendations
	<i>Xeljanz (Oral) Tablet</i>	P/PA
	<i>Xeljanz (Oral) Extended-Release Tablet</i>	P/PA
HAE Treatments		
	<i>Haegarda (Subcutaneous) Injection</i>	NP/PA
	<i>Ruconest (Intravenous) Injection</i>	NP/PA
HIV/AIDS		
	<i>Lamivudine (Oral) Solution</i>	P
	<i>Abacavir/Lamivudine (Oral) Tablet</i>	P
Hypoglycemics, Insulin and Related Agents		
	<i>Humulin 70/30 (Subcutaneous) Vial</i>	P
	<i>Humulin (Subcutaneous) Vial</i>	P
	<i>Humalog 200 units/mL (Subcutaneous) Pen</i>	NP
Laxatives & Cathartics		
	<i>Gavilyte-H/Bisacodyl (Oral) Solution</i>	NP
Lipotropics, Other		
	<i>Fenofibrate (Oral) Tablet [generic Lofibra]</i>	NP
	<i>Triglide (Oral) Tablet</i>	NP
	<i>Fenofibrate (Oral) Capsule [generic Lipofen]</i>	NP
	<i>Fenofibrate (Oral) Micronized Capsule [generic Antara]</i>	NP
Pancreatic Enzymes		
	<i>Zenpep (Oral) Capsule</i>	P
Phosphate Binders		
	<i>Phoslyra (Oral) Solution</i>	NP/PA
	<i>Calcium Acetate (Oral) Tablet</i>	NP/PA
Smoking Cessation		



Therapeutic Class	Drug Name	DURB Recommendations
	<i>Chantix (Oral) Dose Pack</i>	P
	<i>Chantix (Oral) Tablet</i>	P
Ulcerative Colitis Agents		
	<i>Mesalamine (Rectal) Enema Suspension</i>	NP/PA
	<i>Mesalamine (Rectal) Enema Suspension Kit</i>	NP/PA
<i>For the following therapeutic classes, the DUR Board recommended no changes:</i>		
<i>Androgenic Agents</i>	<i>Growth Factors</i>	<i>Multiple Sclerosis Agents</i>
<i>Angiotensin Modulators</i>	<i>Growth Hormone</i>	<i>Opiate Dependence Treatments</i>
<i>Antibiotics, Inhaled</i>	<i>Hepatitis C Agents</i>	<i>PAH Agents, Oral and Inhaled</i>
<i>Antifibrinolytic Agents</i>	<i>Hyperparathyroid Agents</i>	<i>Platelet Aggregation Inhibitors</i>
<i>Antifungals, Vaginal</i>	<i>Hypoglycemics, Incretin Mimetics/Enhancers</i>	<i>Prenatal Vitamins</i>
<i>Antiparasitics, Topical</i>	<i>Hypoglycemics, SGLT2</i>	

P=preferred; NP=non-preferred; PA=prior authorization